About Transposon Therapeutics
Transposon Therapeutics is a private company based in San Diego, California, incorporated in 2019 in Delaware. It has reported $59,121,723 raised in four offerings on Form D since May 2020. Its chief executive is Dennis Podlesak.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 10, 2024 | Jul 15, 2024 | $4,679,395of $20.0M target | 8 | $584K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 20, 2022 | Dec 29, 2022amended Jan 12, 2023 | $5,005,000of $20.0M target | 8 | $625K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 25, 2020 | Dec 9, 2020 | $45,187,328fully sold | 10 | $4.5M | Equity, Options, Securities on exercise, Series A Preferred Stock and the underlying Common Stock issuable upon its conversion.Rule 506(b) | Form D ↗ |
| Apr 21, 2020 | May 6, 2020 | $4,250,000of $6.5M target | 4 | $1.0M | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, four offerings | $59,121,723 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Transposon Therapeutics's Form D filed Jul 15, 2024.
KK
Keith Katkin
Director
DP
Dennis Podlesak
Chief Executive Officer and director
LR
DM
Daniel Hetu, MD, MBA
Director
EM
Eckard Weber, MD
Executive officer and director
BA
Brent Ahrens
Director
BM
Brian Slingsby, MD, PHD, MPH
Director
WM
William Harrington, MD, MBA
Director
JP
John Pacifico
Director
Earlier filings also listed Eckard Weber, M.D. (executive officer and director, last listed Dec 2020).